ERBB2 and breast cancer: The majority of prognostic markers, which are overexpressed in patients with good prognosis in ER-negative breast cancer including HER2-overexpressing breast cancer and triple-negative breast cancer [5], associated with the activation of complement and immune response pathways [6].